Fusion Pharmaceuticals (NASDAQ:FUSN) Hits New 1-Year High at $21.12

Fusion Pharmaceuticals Inc. (NASDAQ:FUSNGet Free Report)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $21.12 and last traded at $21.09, with a volume of 20547677 shares changing hands. The stock had previously closed at $10.64.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on FUSN. William Blair reissued an “outperform” rating on shares of Fusion Pharmaceuticals in a research note on Friday, January 5th. Wedbush reissued a “neutral” rating and issued a $24.00 target price on shares of Fusion Pharmaceuticals in a research note on Tuesday. SVB Leerink reissued a “market perform” rating and issued a $21.00 target price (up previously from $17.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday. Bloom Burton reissued a “buy” rating on shares of Fusion Pharmaceuticals in a research note on Friday, January 5th. Finally, Raymond James boosted their target price on shares of Fusion Pharmaceuticals from $15.00 to $16.00 and gave the company a “strong-buy” rating in a research note on Friday, January 5th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $17.50.

Check Out Our Latest Analysis on Fusion Pharmaceuticals

Fusion Pharmaceuticals Trading Up 97.3 %

The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -12.88 and a beta of -0.85. The company’s 50 day moving average is $10.78 and its 200 day moving average is $6.78. The company has a debt-to-equity ratio of 0.18, a quick ratio of 11.63 and a current ratio of 11.63.

Institutional Investors Weigh In On Fusion Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC boosted its stake in shares of Fusion Pharmaceuticals by 883.0% in the 4th quarter. Signaturefd LLC now owns 2,949 shares of the company’s stock valued at $28,000 after purchasing an additional 2,649 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Fusion Pharmaceuticals by 2,064.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,008 shares of the company’s stock valued at $29,000 after acquiring an additional 2,869 shares during the period. New York State Common Retirement Fund acquired a new stake in shares of Fusion Pharmaceuticals in the 4th quarter valued at approximately $64,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Fusion Pharmaceuticals in the 4th quarter valued at approximately $80,000. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Fusion Pharmaceuticals in the 4th quarter valued at approximately $110,000. Institutional investors own 72.85% of the company’s stock.

Fusion Pharmaceuticals Company Profile

(Get Free Report)

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.

Recommended Stories

Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.